China Pharmaceutical Market Overview:
The China pharmaceutical market is projected to exhibit a growth rate (CAGR) of 7.50% during 2024-2032. The market is driven by numerous factors, which include the rising geriatric population, increasing number of healthcare facilities like hospitals and clinics, prevalence of chronic diseases such as diabetes, arthritis, and cardiovascular issues.
Report Attribute
|
Key Statistics
|
Base Year
|
2023 |
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Growth Rate (2024-2032) |
7.50% |
China Pharmaceutical Market Trends:
Rising Geriatric Population
The growing demand for pharmaceutical products among the geriatric population, as they are more prone to chronic diseases, is influencing the market positively. Elderly individuals are more vulnerable to conditions like diabetes, heart problems, and cancer as they get older. This demographic trend in China creates a substantial and growing market for pharmaceutical products tailored for managing and treating these chronic conditions. In addition, the market is expanding as a result of increasing awareness among individuals about the importance of early diagnosis, treatment, and management of chronic illnesses. Furthermore, pharmaceutical companies are putting more and more effort into creating drugs that are specially designed to meet the needs of elderly individuals. These medications include formulations that are designed to be easier to administer, have reduced side effects, and are more effective in managing age-related conditions. Companies are also focusing on producing more cost-effective pharmaceutical products to make them accessible to a larger elderly population in China. The population of people over 60 years old in the country is projected to reach 28% by 2040, due to longer life expectancy and declining fertility rates, as stated by the World Health Organization (WHO).
Increasing Number of Healthcare Facilities
As per CEIC, the number of hospitals in China were reported 39,000.000 unit in 2023 year, an increase as compared to 2022. The rising utilization of pharmaceutical products in hospitals, clinics, surgical centers, and nursing homes is bolstering the market growth. These facilities have huge patient influxes that are suffering from a wide range of disorders. Healthcare providers are prescribing various drugs that are beneficial in their healing process. Furthermore, governing authorities in China are concentrating on enhancing healthcare facilities by financing the purchase of advanced machinery and medical equipment. They are also focusing on providing numerous tax breaks, financial incentives, and support for biotech startups and innovation hubs, in addition to granting various product approvals.
China Pharmaceutical Market News:
- 20 March 2024: Sinopharm signed a strategic cooperation agreement with Fresenius Kabi (China) Co Ltd. This aims to further consolidate and expand cooperation in areas like pharmaceutical sales, warehousing, distribution, healthcare, and medical care and wellness, with the goal of bringing better products and services to the Chinese people.
- 30 October 2023: Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui) collaborated with Merck, a leading science and technology company. The partnership includes an exclusive license worldwide to develop, manufacture, and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167. The agreement also includes an option for an exclusive license worldwide to develop, manufacture, and commercialize Hengrui’s Claudin-18.2 antibody-drug conjugate (ADC) SHR-A1904.
China Pharmaceutical Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on type and nature.
Type Insights:
- Pharmaceutical Drugs
- Cardiovascular Drugs
- Dermatology Drugs
- Gastrointestinal Drugs
- Genito-Urinary Drugs
- Hematology Drugs
- Anti-Infective Drugs
- Metabolic Disorder Drugs
- Musculoskeletal Disorder Drugs
- Central Nervous System Drugs
- Oncology Drugs
- Ophthalmology Drugs
- Respiratory Diseases Drugs
- Biologics
- Monoclonal Antibodies (MAbS)
- Therapeutic Proteins
- Vaccines
The report has provided a detailed breakup and analysis of the market based on the type. This includes pharmaceutical drugs (cardiovascular drugs , dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorder drugs, musculoskeletal disorder drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs) and biologics (monoclonal antibodies (MAbS), therapeutic proteins, and vaccines).
Nature Insights:
A detailed breakup and analysis of the market based on the nature have also been provided in the report. This includes organic and conventional.
Region Insights:
- North China
- East China
- South Central China
- Southwest China
- Northwest China
- Northeast China
The report has also provided a comprehensive analysis of all the major regional markets, which include North China, East China, South Central China, Southwest China, Northwest China, and Northeast China.
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
China Pharmaceutical Market Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Types Covered |
- Pharmaceutical Drugs: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs
- Biologics: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines
|
Natures Covered |
Organic, Conventional |
Regions Covered |
North China, East China, South Central China, Southwest China, Northwest China, Northeast China |
Customization Scope |
10% Free Customization |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the China pharmaceutical market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the China pharmaceutical market?
- What is the breakup of the China pharmaceutical market on the basis of type?
- What is the breakup of the China pharmaceutical market on the basis of nature?
- What are the various stages in the value chain of the China pharmaceutical market?
- What are the key driving factors and challenges in the China pharmaceutical?
- What is the structure of the China pharmaceutical market and who are the key players?
- What is the degree of competition in the China pharmaceutical market?
Key Benefits for Stakeholders:
- IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the China pharmaceutical market from 2018-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the China pharmaceutical market.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the China pharmaceutical industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.